Stockscreener 앱 받기
6.71
0.30%
0.02
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential By Investing.com - Investing.com Nigeria
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential - Investing.com India
(ACRV) Technical Data - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ACRV Earnings - MarketBeat
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Simply Wall St
Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright - Defense World
BMO Capital Markets Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $27.00 - Defense World
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results - TipRanks
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright - MarketBeat
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position | ACRV Stock News - StockTitan
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Average PT from Analysts - Defense World
Trend Tracker for (ACRV) - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com Canada
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa
(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ACRV) Investment Analysis and Advice - Stock Traders Daily
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel - The Bakersfield Californian
Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Bought by Marshall Wace LLP - MarketBeat
Perceptive Advisors LLC Acquires 2,353,000 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - MarketBeat
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expands By 24.3% - MarketBeat
Wall Street SWOT: Acrivon Therapeutics stock shows promise amid oncology challenges - Investing.com
The Potential Rise in the Price of ACM Research Inc (ACMR) following insiders activity - Knox Daily
Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com
Capricor Therapeutics price target raised to $25 from $12 at Maxim - TipRanks
Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha
DRW Securities LLC Invests $287,000 in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
You might want to take a look at ACM Research Inc (ACMR) now - SETE News
When the Price of (ACRV) Talks, People Listen - Stock Traders Daily
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance
Benjamin F. Edwards & Company Inc. Has $847,000 Stock Position in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
2.88%
2.65%
자본화:
|
볼륨(24시간):